Definitive Contract HHSO100201700023C
Award Date
9/13/17
Potential Completion Date
6/30/22
Potential Value
$7.5M
Awardee
Mapp Biopharmaceutical, Inc.
Ultimate Awardee
Not listed
NAICS Category
541711 - Research and Development in Biotechnology
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Cost Plus Fixed Fee
Place of Performance
San Diego, CA 92121, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a $30,920,844.79 cost-plus-fixed-fee contract awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR) to Mapp Biopharmaceutical, Inc., a San Diego-based biotechnology company. The contract is for an Expanded Access Protocol for ZMapp, a medical countermeasure against the Ebola virus. This appears to be a follow-on to a previous contract (75A50122C00061) with Mapp Biopharmaceutical. The contract has no set-aside designation and is focused on advancing...
This is a $293,443,870.00 definitive contract awarded by the Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response (ASPR) to Mapp Biopharmaceutical, Inc., a San Diego-based biotechnology company. The contract is for the provision of therapeutic interventions and medical countermeasures against infectious diseases and biothreats, including viral hemorrhagic fevers like Ebola, Marburg, and Lassa, as well as botulinum neurotoxin. Mapp...
This is a $906,651,397.58 cost-plus-fixed-fee definitive contract awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR), a civilian agency, to Mapp Biopharmaceutical, Inc., a for-profit biotechnology company based in San Diego, California. The contract is for the procurement of therapeutics for Ebola, Sudan, and Marburg viruses, with a period of performance running through September 29, 2032. This contract has no set-aside designation. Mapp Biopharmaceutical is...
This is a $62,511,942.00 cost-plus-fixed-fee definitive contract awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR), a civilian agency within the U.S. Department of Health and Human Services, to Mapp Biopharmaceutical, Inc., a biotechnology company based in San Diego, California. The contract is for the development of an anti-Sudan ebolavirus medical countermeasure, a critical public health and national security priority. Mapp Biopharmaceutical has a strong...
This is a federal contract awarded by the Defense Threat Reduction Agency (DTRA), a defense agency, to Mapp Biopharmaceutical, Inc., a biotechnology company specializing in the development of antibody-based therapeutics and medical countermeasures against infectious diseases and biothreats. The contract, valued at $6,173,324.00, is for research and development services during the base period, with a period of performance ending on August 31, 2017. The contract is a Cost Plus Fixed Fee Definitive...
This is a $30,559,760.00 cost-plus-fixed-fee delivery order awarded by the U.S. Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response to Emergent Manufacturing Operations Baltimore LLC, a for-profit manufacturer of medical countermeasures. The contract is for the development of the MAPP biopharmaceutical Viral Hemorrhagic Fever (VHF) Medical Countermeasure (MCM) platform. This work is being performed under the Centers for Innovation in...
This is a Definitive Contract awarded to Mapp Biopharmaceutical, Inc., a biotechnology company based in San Diego, California, by the Defense Health Agency, a component of the U.S. Department of Defense. The contract has a ceiling value of $1,192,803.19 and is for the BASE YEAR of the MACV Contract, which generates MACV IGG2. The contract is a Firm Fixed Price arrangement with a period of performance through March 1, 2025. There was no set-aside designation for this award. Mapp Biopharmaceutical...
This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the Department of the Army Acquisition Support Center Joint PEO Chemical and Biological Defense to Mapp Biopharmaceutical, Inc., a San Diego-based biotechnology company. The firm-fixed-price purchase order, with a potential value of $149,998.71, is for research and development efforts related to STTR Phase I work. Mapp Biopharmaceutical has extensive experience providing therapeutic interventions and medical...
This is a sole-source contract awarded by the Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response (ASPR) to Ridgeback Biotherapeutics LP for the development and manufacturing of the monoclonal antibody treatment mAb114 for Ebola virus disease (EVD). The contract has a ceiling value of $159,990,035.88 and a period of performance through July 31, 2023. It was awarded on March 19, 2020 as a cost-plus-fixed-fee definitive contract. The...
This is a $111,268,952.26 cost-plus-fixed-fee definitive contract awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR), a civilian agency, to Merck Sharp & Dohme LLC (doing business as Merck), a for-profit pharmaceutical manufacturer. The contract is for the manufacturing and development of the RVSV-ZEBOV vaccine, a critical medical countermeasure. It does not have a set-aside designation. Merck also holds several significant indefinite delivery vehicles...